IGM Biosciences Inc (IGMS)
7.28
-0.66
(-8.31%)
USD |
NASDAQ |
Jun 14, 16:00
7.29
+0.01
(+0.14%)
After-Hours: 20:00
IGM Biosciences Research and Development Expense (Annual): 215.52M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 215.52M |
| December 31, 2022 | 179.29M |
| December 31, 2021 | 127.03M |
| December 31, 2020 | 65.03M |
| Date | Value |
|---|---|
| December 31, 2019 | 35.26M |
| December 31, 2018 | 18.96M |
| December 31, 2017 | 8.639M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
35.26M
Minimum
2019
215.52M
Maximum
2023
124.42M
Average
127.03M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Oragenics Inc | 15.49M |
| Rezolute Inc | 43.81M |
| GT Biopharma Inc | 6.466M |
| 180 Life Sciences Corp | 2.784M |
| Sensei Biotherapeutics Inc | 18.30M |